102 related articles for article (PubMed ID: 33507825)
1. Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study.
Mishuk AU; Chen L; Li C; Huo N; Hansen RA; Harris I; Kiptanui Z; Qian J
Curr Med Res Opin; 2021 Apr; 37(4):655-664. PubMed ID: 33507825
[TBL] [Abstract][Full Text] [Related]
2. Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study.
Li C; Chen L; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Wang Z; Qian J
PLoS One; 2020; 15(4):e0232226. PubMed ID: 32353006
[TBL] [Abstract][Full Text] [Related]
3. Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study.
Chen L; Li C; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Qian J
Curr Med Res Opin; 2020 Sep; 36(9):1533-1540. PubMed ID: 32644886
[TBL] [Abstract][Full Text] [Related]
4. Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study.
Huo N; Chen L; Ullah Mishuk A; Li C; Hansen RA; Harris I; Kiptanui Z; Wang Z; Dutcher SK; Qian J
Endocrine; 2020 May; 68(2):336-348. PubMed ID: 31993992
[TBL] [Abstract][Full Text] [Related]
5. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Hartung DM; Middleton L; Svoboda L; McGregor JC
CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
[TBL] [Abstract][Full Text] [Related]
6. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
9. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
10. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
Rathe JØ
Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
[TBL] [Abstract][Full Text] [Related]
11. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
12. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
[TBL] [Abstract][Full Text] [Related]
13. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
Hansen RA; Qian J; Berg RL; Linneman JG; Seoane-Vazquez E; Dutcher S; Raofi S; Page CD; Peissig PL
Clin Pharmacol Ther; 2018 Feb; 103(2):310-317. PubMed ID: 27981563
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
16. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
[TBL] [Abstract][Full Text] [Related]
17. The risks and costs of multiple-generic substitution of topiramate.
Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
[TBL] [Abstract][Full Text] [Related]
18. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
Lessing C; Ashton T; Davis PB
J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
20. Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting.
Roman B
CNS Drugs; 2009 Aug; 23(8):693-701. PubMed ID: 19594198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
